Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Lupus Innovation Award

Lupus Research Alliance

The Lupus Research Alliance (LRA) is the largest private funder of lupus research worldwide. The organization aims to transform lupus treatment while advancing towards a cure by funding cutting-edge, innovative research.

At present, therapy for lupus is mostly empiric and involves largely non-specific antiinflammatory and immunosuppressive agents. While these treatments are frequently beneficial, many patients do not respond adequately or suffer significant side effects. Importantly, even patients with low disease activity accrue organ damage over time. There are many unanswered questions regarding the pathogenesis of lupus. Thus, new conceptual and therapeutic approaches are urgently needed. To enable the development of more effective and safer lupus therapies, and to address major barriers in lupus research and translation, the LRA has established the Lupus Innovation Award (LIA).

PROGRAM DESCRIPTION The LIA provides up to $150,000 per year for up to two years. Early-stage investigators (ESIs) are eligible for a third year of funding (see Special Considerations section for further details). Both early career and established investigators new to lupus with highly innovative ideas are encouraged to apply.

The LIA supports pioneering, high-risk, high-reward approaches to major challenges in lupus research. The overarching goals of the LIA are to: (1) promote investigation of underexplored pathways and fundamental mechanisms of lupus and its complications and (2) initiate transformative discoveries in lupus that can drive the development of safer and more effective treatments or novel biomarkers. All studies should have a clear and direct relevance to people with lupus and should offer the potential to improve the standard of care for the disease or usher in a cure.

Specialties

Immunology

Pathology

Others

Eligibility Requirements

Individuals with a doctoral degree (MD, PhD, DO, or equivalent), holding a faculty, or equivalent, position and leading an independent research team at an academic, nonprofit, or government research institution are eligible to apply. US federal government research laboratories are not eligible for this award. There are no citizenship requirements for investigators applying to this program.

Applicants who have previously received LRA funding must also be up to date with all reporting requirements and other Terms and Conditions of the original award(s) at the time of applying.

The same research project may not be submitted for consideration to multiple LRA grant mechanisms in the same year. Such submissions will be triaged without review.

Continuations of long-term research projects are not appropriate for this grant mechanism.

Sponsor Details

Sponsor Institute/Organizations: Lupus Research Alliance

Sponsor Type:

Address: 270 Madison Avenue, Suite 300, New York, NY 10016

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity